Praxis Precision Medicines Quarterly Income Statements Chart
Quarterly
|
Annual
Praxis Precision Medicines Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration revenue | 7,463,000 | 302,000 | 357,000 | 431,000 | 515,000 | 468,000 | 781,000 | 683,000 | ||||||||||||
| operating expenses: | ||||||||||||||||||||
| research and development | 63,006,000 | 60,806,000 | 56,288,000 | 41,881,000 | 27,260,000 | 26,984,000 | 18,388,000 | 17,260,000 | 25,614,000 | 25,504,000 | 28,329,000 | 30,439,000 | 43,620,000 | 52,652,000 | 43,511,000 | 33,139,000 | 25,678,000 | 17,929,000 | 16,272,000 | 12,786,000 |
| general and administrative | 13,061,000 | 13,922,000 | 15,131,000 | 15,256,000 | 10,585,000 | 15,333,000 | 9,933,000 | 8,724,000 | 10,127,000 | 13,270,000 | 13,124,000 | 13,851,000 | 16,774,000 | 16,197,000 | 15,146,000 | 11,634,000 | 10,805,000 | 9,490,000 | 9,440,000 | 3,431,000 |
| total operating expenses | 76,067,000 | 74,728,000 | 71,419,000 | 57,137,000 | 37,845,000 | 42,317,000 | 28,321,000 | 25,984,000 | 35,741,000 | 38,774,000 | 41,453,000 | 44,290,000 | 60,394,000 | 68,849,000 | 58,657,000 | 44,773,000 | 36,483,000 | 27,419,000 | 25,712,000 | 16,217,000 |
| income from operations | -76,067,000 | -74,728,000 | -63,956,000 | -56,835,000 | -37,488,000 | -41,886,000 | -27,806,000 | -25,516,000 | -34,960,000 | -38,091,000 | -41,453,000 | -44,290,000 | -60,394,000 | -68,849,000 | -58,657,000 | -44,773,000 | -36,483,000 | -27,419,000 | -25,712,000 | -16,217,000 |
| yoy | 102.91% | 78.41% | 130.01% | 122.74% | 7.23% | 9.96% | -32.92% | -42.39% | -42.11% | -44.67% | -29.33% | -1.08% | 65.54% | 151.10% | 128.13% | 176.09% | ||||
| qoq | 1.79% | 16.84% | 12.53% | 51.61% | -10.50% | 50.64% | 8.97% | -27.01% | -8.22% | -8.11% | -6.41% | -26.66% | -12.28% | 17.38% | 31.01% | 22.72% | 33.06% | 6.64% | 58.55% | |
| operating margin % | ||||||||||||||||||||
| other income: | ||||||||||||||||||||
| other income | 4,940,000 | 5,432,000 | 5,277,000 | 4,925,000 | 4,811,000 | 2,333,000 | 928,000 | 884,000 | 648,000 | 636,000 | 280,000 | 345,000 | 200,000 | 132,000 | 70,000 | 73,000 | 82,000 | |||
| total other income | 4,940,000 | 5,432,000 | 5,277,000 | 4,925,000 | 4,811,000 | 2,333,000 | 928,000 | 884,000 | 648,000 | 636,000 | 280,000 | 345,000 | 200,000 | 132,000 | 70,000 | 73,000 | 82,000 | 46,000 | 6,000 | 1,000 |
| net income | -71,127,000 | -69,296,000 | -58,679,000 | -51,910,000 | -32,677,000 | -39,553,000 | -26,878,000 | -24,632,000 | -34,312,000 | -37,455,000 | -41,173,000 | -43,945,000 | -60,194,000 | -68,717,000 | -58,582,000 | -44,705,000 | -36,401,000 | -27,373,000 | ||
| yoy | 117.67% | 75.20% | 118.32% | 110.74% | -4.77% | 5.60% | -34.72% | -43.95% | -43.00% | -45.49% | -29.72% | -1.70% | 65.36% | 151.04% | ||||||
| qoq | 2.64% | 18.09% | 13.04% | 58.86% | -17.38% | 47.16% | 9.12% | -28.21% | -8.39% | -9.03% | -6.31% | -26.99% | -12.40% | 17.30% | 31.04% | 22.81% | 32.98% | |||
| net income margin % | ||||||||||||||||||||
| net income per share | -3.31 | -3.29 | -3 | -2.75 | -1.74 | -2.84 | -17.57 | -0.18 | -0.49 | -0.71 | -0.85 | -0.96 | -1.32 | -1.51 | -1.33 | -1 | -0.88 | -0.71 | 18.67 | -12.1 |
| weighted-average common shares outstanding, basic and diluted | 21,474,827 | 21,055,834 | 17,906,794 | 135,591,429 | 69,740,719 | 53,102,907 | 46,096,737 | 45,774,376 | 45,542,600 | 45,455,179 | 42,454,055 | 44,714,941 | 41,569,782 | 38,470,710 | 8,950,152 | 1,665,902 | ||||
| weighted-average common shares outstanding, basic and diluted1 | 18,884,562 | 18,824,479 | 13,904,374 | 6,594,316 | ||||||||||||||||
| income before income taxes | -43,214,000 | -43,945,000 | -58,587,000 | -44,700,000 | -36,401,000 | |||||||||||||||
| benefit from income taxes | -1,250 | -5,000 | ||||||||||||||||||
| accretion and cumulative dividends on redeemable convertible preferred stock | -950,000 | -3,943,000 | ||||||||||||||||||
| gain on repurchase of redeemable convertible preferred stock | ||||||||||||||||||||
| net income attributable to common stockholders | -58,582,000 | -44,705,000 | -36,401,000 | -27,373,000 | -26,656,000 | -20,159,000 | ||||||||||||||
| interest income | 46,000 | 6,000 | 1,000 | |||||||||||||||||
| income before benefit from income taxes | -27,373,000 | -25,706,000 | -16,216,000 | |||||||||||||||||
| net income and comprehensive loss | -25,706,000 | -16,216,000 |
We provide you with 20 years income statements for Praxis Precision Medicines stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Praxis Precision Medicines stock. Explore the full financial landscape of Praxis Precision Medicines stock with our expertly curated income statements.
The information provided in this report about Praxis Precision Medicines stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.